Goldman Sachs
RCKT icon

Goldman Sachs’s Rocket Pharmaceuticals RCKT Stock Holding History

Goldman Sachs’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-90,250
Closed -$2.2M – 6960
2016
Q4 		$2.2M Hold
90,250
– – ﹤0.01% 3762
2016
Q3 		$3.42M Buy
+90,250
New +$2.84M ﹤0.01% 3372

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's RCKT Position: Q1 2026 in Review

Goldman Sachs increased its Rocket Pharmaceuticals (RCKT) stake by 84% in Q1 2026, buying an estimated $3.12M and bringing the position to 1,721,116 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3492.

Goldman Sachs first reported a position in RCKT in Q2 2015 and has held it in 39 quarters since. The position peaked at $51.8M in Q4 2020. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Goldman Sachs held 1,721,116 shares of Rocket Pharmaceuticals worth $6.16M as of Q1 2026.
  • Goldman Sachs bought 784,522 Rocket Pharmaceuticals shares in Q1 2026, an estimated $3.12M.
  • Rocket Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3492 holding.
  • Goldman Sachs first reported a position in Rocket Pharmaceuticals in Q2 2015 and has held it in 39 quarters since.
  • Goldman Sachs's Rocket Pharmaceuticals position peaked at $51.8M in Q4 2020.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.